Go to deals
Healthcare

Fine Foods & Pharmaceuticals N.T.M. has finalized the translisting to the Euronext Milan, STAR market

Fine Foods Pharmaceuticals N.T.M. SpA has completed the translisting from the Euronext Growth Milan to the Euronext Milan, STAR segment.

Fine Foods & Pharmaceuticals N.T.M. operates as a contract development and manufacturing organization for the pharmaceutical industry. The firm specializes in the distribution of oral solid forms for the pharmaceutical and nutraceutical industries. It also offers medical devices and technologies for granulation and packaging.

Oaklins Italy’s parent company Banca Akros acted as sponsor in the translisting of Fine Foods Pharmaceuticals N.T.M.

Talk to the deal team

Giulio Greco

Managing Director
Milan, Italy
Oaklins Italy

Marco Valsecchi

Associate
Milan, Italy
Oaklins Italy

Related deals

MEDIK Hospital Design Group has been acquired by STERIS
Construction & Engineering Services | Healthcare

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Learn more
Electro Optic Systems has acquired the UK interceptor business of MARSS
Aerospace, Defense & Security

Electro Optic Systems has acquired the UK interceptor business of MARSS

Electro Optic Systems Holdings Limited (ASX: EOS) has acquired the UK-based interceptor unmanned aerial system business of MARSS Group for US$6.4 million (€5.5 million). The interceptor is a reusable electric drone effector guided by imaging sensors and AI, which EOS will integrate into its counter-drone portfolio for defense and critical infrastructure customers. EOS plans further investment to complete development.

Learn more
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Healthcare

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Learn more